Lucira Health

Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company was founded by Debkishore Mitra, John Robert Waldeisen and Benjamin Ross in 2013 and is headquartered in Emeryville, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.

The stock price of Lucira Health Inc (NASDAQ: LHDX) increased by over 5% pre-market. This is why it happened.

LHDX Stock: Over 5% Increase Pre-Market Explanation

EMERYVILLE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will be participating in the BofA Securities 2021 Virtual Healthcare Conference.

Lucira Health to Participate in Upcoming BofA Securities 2021 Virtual Healthcare Conference

This coronavirus testing stock has taken shareholders on a roller-coaster ride since its IPO.

Is Lucira Health a Buy?

EMERYVILLE, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter ended March 31, 2021 financial results on Thursday, May 13, 2021. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Lucira Health to Announce First Quarter 2021 Financial Results

Jabil

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the opening of a new production center in the Dominican Republic by its manufacturing partner Jabil Inc. (NYSE: JBL). The new facility will increase production of the LUCIRA CHECK IT™ COVID-19 test kit during the second quarter of 2021. Jabil also manufactures Lucira's

Lucira Health Celebrates Grand Opening of New Jabil Manufacturing Plant, Increasing Production of LUCIRA CHECK IT™ COVID-19 Self-Test

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that Health Canada issued an Authorization with Conditions for the LUCIRA™ CHECK IT COVID-19 test kit. The Authorization with Conditions was issued by Health Canada under the Interim Order (IO) Respecting the Importation and Sale of Medical Devices for Use in Relation

Health Canada Authorizes First COVID-19 Test For Self-Testing At Home

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that for the first time ever, NBA fans can test themselves for COVID-19 before attending a live game. This program supports the Friday Chase Center reopening in San Francisco as the Golden State Warriors host the Denver Nuggets. People buying tickets more than seven da

For the First Time Ever, NBA Fans Can Test Themselves for COVID-19 Before Attending a Live Game. Testing Program Debuts in San Francisco Bay Area this Friday with LUCIRA™ Check It COVID-19 At-Home Test

This analyst thinks the company's stock performance will trail that of the market.

Why Lucira Health Stock Is Plunging Today

The company's COVID-19 Test Kit will soon be available for sale at a pharmacy near you.

Why Lucira Health Stock Skyrocketed Today

The stock price of Lucira Health Inc (NASDAQ: LHDX) increased by over 40% during intraday trading. This is why it happened.

LHDX Stock: Over 40% Increase Intraday Explanation

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of the LUCIRA CHECK IT™ test kit that delivers PCR quality molecular accuracy in 30 minutes or less at home. It is authorized and available for indiv

FDA Authorizes First Single-Use, PCR Quality Over the Counter (OTC) LUCIRA CHECK IT™ COVID-19 At-Home Test. Available Now.

Perdoceo Education

Vertex, Inc.

After the sell-off in February, the markets have sprung back up. The broader S&P 500 Index is trading at an all-time high and the blue-chip Dow Jones Industrial Index is just shy of its all-time peak.

3 Stocks Near 52-Week Lows That Could Bounce Back

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today confirmed it can successfully identify the “double mutant” variant of COVID-19 with its Lucira molecular test kit. The “double mutant” variant was first identified in India on March 24, 2021, and found in California on March 25, 2021, by Stanford Clinical Virology Lab scientists

LUCIRA COVID-19 Test Kit Identifies Viral Variants

Demand for COVID-19 testing is massive (demand for tests measured in the billions) and sustainable for many years to come. LHDX sales will be limited by production, not demand. We believe the winner in COVID-19 testing will have: 1) Fast turnaround times, 2) convenience, 3) accuracy and 4) being price competitive. Importantly, we believe speed, convenience, and accuracy will win.

Lucira Health's COVID-19 Molecular Testing Kits Dubbed The Gold Standard

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (Nasdaq: LHDX), today announced that U.S. physicians and healthcare providers can now order Lucira COVID-19 All-In-One Test Kits online from lucirahealth.com. This U.S. made and manufactured product is the first FDA authorized, prescription, molecular diagnostic test for COVID-19 that can be self-administered in a physician's office, or used by patients at home. Each single-use test kit costs $50 and contains everything needed to conduct

U.S. Physicians Can Now Order Lucira Health Self-Administered, Lab Quality, COVID-19 Molecular Test for Home or Office

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the closing of its upsized initial public offering of 10,350,000 shares of its common stock, which includes 1,350,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares, at a public offering price

Lucira Health Announces Closing of its Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

The stock price of Lucira Health, Inc. (NASDAQ: LHDX) increased by 46.94% on Friday, February 5. This is why it happened.

LHDX Stock Price Increased 46.94%: Why It Happened

Angion Biomedica

Atotech

Bolt Biotherapeutics

Immunocore Holdings

Landos Biopharma

ON24

Pharvaris B.V.

Sana Biotechnology

Sensei Biotherapeutics

Terns Pharmaceuticals

TELUS International (Cda)

Vor Biopharma

The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.

U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week

A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well.

The Biotech IPO Wave Continues. Here Are 7 Stocks Hitting the Market.

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the pricing of its upsized initial public offering of 9,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Lucira from the offering, before deducting underwriting discounts and commissions and estimated off

News for Lucira Health Stock (LHDX)